Fluticasone propionate
/ Fluticasone, Advair, Airduo, Avamys, Dymista, Ellipta, Flonase, Flovent, Fluticasone, Fluticasone /, Spiromax, Wixela, Xhance (fluticasone propionate) is a small molecule pharmaceutical. Fluticasone propionate was first approved as Cutivate on 1990-12-14. It is used to treat allergic rhinitis perennial in the USA. It has been approved in Europe to treat allergic rhinitis perennial, allergic rhinitis seasonal, asthma, and chronic obstructive pulmonary disease. The pharmaceutical is active against glucocorticoid receptor. In addition, it is known to target mineralocorticoid receptor and progesterone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 24 hour allergy nasal | ANDA | 2023-10-11 |
| advair | New Drug Application | 2024-02-27 |
| advair diskus | New Drug Application | 2024-01-30 |
| advair hfa | New Drug Application | 2024-05-23 |
| airduo digihaler | New Drug Application | 2024-04-29 |
| airduo respiclick | New Drug Application | 2024-02-06 |
| allergy nasal | ANDA | 2024-12-18 |
| allergy relief | ANDA | 2025-02-28 |
| allergy relief nasal | ANDA | 2024-11-27 |
| armonair digihaler | New Drug Application | 2024-04-29 |
Show 64 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FLUTICASONE FUROATE / VILANTEROL TRIFENATATE, BREO ELLIPTA, GLAXO GRP LTD | |||
| 2026-11-13 | PED | ||
| 2026-05-13 | NPP, NS | ||
FLUTICASONE FUROATE, ARNUITY ELLIPTA, GLAXOSMITHKLINE | |||
| 2026-03-01 | M-290 | ||
FLUTICASONE PROPIONATE, ARMONAIR DIGIHALER, TEVA PHARM | |||
| 2025-01-09 | PED | ||
| 2024-07-09 | NPP, NS | ||
FLUTICASONE PROPIONATE, ARMONAIR RESPICLICK, TEVA PHARM | |||
| 2025-01-09 | PED | ||
| 2024-07-09 | NPP, NS | ||
FLUTICASONE PROPIONATE / SALMETEROL XINAFOATE, AIRDUO DIGIHALER, TEVA PHARM | |||
| 2025-01-09 | PED | ||
| 2024-07-09 | M-61 | ||
FLUTICASONE PROPIONATE / SALMETEROL XINAFOATE, AIRDUO RESPICLICK, TEVA PHARM | |||
| 2025-01-09 | PED | ||
| 2024-07-09 | M-61 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Fluticasone Propionate, Armonair Digihaler, Teva Pharm | |||
| 11266796 | 2041-02-22 | DP | |
| 11173259 | 2040-07-06 | DP | |
| 11464923 | 2040-06-19 | DP | |
| 11439777 | 2040-05-24 | DP | |
| 11344685 | 2039-09-26 | DP | |
| 11000653 | 2038-12-18 | DP | |
| 11357935 | 2038-09-24 | DP | |
| 11351317 | 2038-02-10 | DP | |
| 10569034 | 2036-08-16 | DP | |
| 10918816 | 2035-12-14 | DP | |
| 9782550 | 2035-08-28 | DP | |
| 9782551 | 2035-08-28 | DP | |
| 8714149 | 2032-02-25 | DP | |
| 8978966 | 2032-01-13 | DP | |
| 10561808 | 2032-01-01 | DP | |
| 9216260 | 2031-06-28 | DP | |
| 9731087 | 2031-05-18 | DP | |
| 10022510 | 2031-05-18 | DP | |
| 10124131 | 2031-05-18 | DP | |
| 10195375 | 2031-02-14 | DP | |
| 8651103 | 2028-03-26 | DP | |
| 9463288 | 2025-05-19 | DP | |
| 10765820 | 2025-05-19 | DP | |
| 9616024 | 2024-09-01 | DP | |
| Fluticasone Propionate, Xhance, Optinose Us Inc | |||
| 11554229 | 2036-02-23 | U-2133 | |
| 10300229 | 2035-07-07 | DP | U-2133 |
| 10076614 | 2034-10-20 | DP | |
| 10478574 | 2033-11-04 | U-2133 | |
| 10179216 | 2033-07-08 | DP | U-2133 |
| 11033696 | 2033-05-20 | DP | |
| 10252010 | 2031-02-07 | DP | |
| 8978647 | 2030-12-06 | DP | |
| 8550073 | 2029-10-22 | DP | |
| 10076615 | 2029-07-30 | U-2133 | |
| 11602603 | 2028-10-27 | DP | U-2133 |
| 10124132 | 2027-03-06 | DP | U-2133 |
| 7975690 | 2025-12-29 | U-2133 | |
| 8522778 | 2024-04-20 | DP | |
| Fluticasone Propionate / Salmeterol Xinafoate, Airduo Digihaler, Teva Pharm | |||
| 9066957 | 2034-10-06 | DP | U-645 |
| 9415008 | 2034-10-06 | DP | U-645 |
| 9987229 | 2024-09-01 | DP | |
| Fluticasone Furoate / Umeclidinium Bromide / Vilanterol Trifenatate, Trelegy Ellipta, Glaxosmithkline | |||
| 9750726 | 2030-11-29 | DP | |
| 11090294 | 2030-11-29 | U-3202 | |
| 8534281 | 2030-03-08 | DP | |
| 8161968 | 2028-02-05 | DP | |
| 7488827 | 2027-12-18 | DS, DP | |
| 8511304 | 2027-06-14 | DP | U-1424, U-1691, U-2954, U-3623 |
| 8183257 | 2025-07-27 | U-2128, U-2129 | |
| 7439393 | 2025-05-21 | DS, DP | U-1401, U-1691, U-2099, U-2100, U-2127, U-2957, U-3623 |
| 7498440 | 2025-04-27 | DS, DP | |
| 8309572 | 2025-04-27 | U-2129 | |
| Fluticasone Furoate, Arnuity Ellipta, Glaxosmithkline | |||
| 8746242 | 2030-10-11 | DP | |
| 8201556 | 2029-02-05 | DP | |
| 9333310 | 2027-10-02 | DP | |
| Fluticasone Furoate / Vilanterol Trifenatate, Breo Ellipta, Glaxo Grp Ltd | |||
| 11116721 | 2029-02-26 | DP | U-1401, U-1691, U-3623 |
| Fluticasone Furoate, Flonase Sensimist Allergy Relief, Haleon Us Holdings | |||
| 8147461 | 2028-10-15 | DP | |
| 8347879 | 2028-07-15 | DP | |
| 8062264 | 2026-04-05 | DP | |
| 9320862 | 2024-11-06 | DP | |
| Fluticasone Propionate, Flovent Hfa, Glaxo Grp Ltd | |||
| 7500444 | 2026-02-26 | DP | |
| Azelastine Hydrochloride / Fluticasone Propionate, Dymista, Mylan Speciality Lp | |||
| 8168620 | 2026-02-24 | DP | |
ATC Codes
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AC: Corticosteroids, potent (group iii)
— D07AC17: Fluticasone
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AD: Corticosteroid nasal preparations for topical use
— R01AD08: Fluticasone
— R01AD12: Fluticasone furoate
— R01AD58: Fluticasone, combinations
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AK: Adrenergics inhalants in combination with corticosteroids or other drugs, excl. anticholinergics
— R03AK06: Salmeterol and fluticasone
— R03AK10: Vilanterol and fluticasone furoate
— R03AK11: Formoterol and fluticasone
— R03AL: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
— R03AL08: Vilanterol, umeclidinium bromide and fluticasone furoate
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BA: Glucocorticoid inhalants for obstructive airway disease
— R03BA05: Fluticasone
— R03BA09: Fluticasone furoate
HCPCS
No data
Clinical
Clinical Trials
841 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis | D065631 | — | J30.9 | — | 1 | — | — | — | 1 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | 1 | — | — | — | 1 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fluticasone propionate |
| INN | fluticasone |
| Description | Fluticasone propionate is a trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity. It has a role as an anti-allergic agent, an anti-asthmatic drug, an anti-inflammatory drug, a dermatologic drug, a bronchodilator agent and an adrenergic agent. It is a corticosteroid, a steroid ester, an 11beta-hydroxy steroid, a propanoate ester, a fluorinated steroid, a thioester and a 3-oxo-Delta(1),Delta(4)-steroid. It is functionally related to a fluticasone. It derives from a hydride of an androstane. |
| Classification | Small molecule |
| Drug class | Steroids and steroid derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 80474-14-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1473 |
| ChEBI ID | 31441 |
| PubChem CID | 444036 |
| DrugBank | DB00588 |
| UNII ID | CUT2W21N7U (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
NR3C2
NR3C2
PGR
PGR
Organism
Homo sapiens
Gene name
NR3C2
Gene synonyms
MCR, MLR
NCBI Gene ID
Protein name
mineralocorticoid receptor
Protein synonyms
aldosterone receptor, mineralocorticoid receptor 1, mineralocorticoid receptor 2, mineralocorticoid receptor delta, Nuclear receptor subfamily 3 group C member 2
Uniprot ID
Mouse ortholog
Nr3c2 (110784)
mineralocorticoid receptor (Q8VII9)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,016 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
161,793 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use